Before Foundayo arrived in April 2026, there was the Wegovy pill. On December 22, 2025, the FDA approved oral semaglutide 25 mg — sold under the Wegovy name — making it the first oral GLP-1 medication ever specifically approved for chronic weight management. It launched commercially in January 2026, giving patients who wanted semaglutide’s proven results without a weekly injection their first real option.
This guide covers the Wegovy pill’s approval, how it differs from injectable Wegovy and from Rybelsus, what the pivotal OASIS 4 trial showed, and the strict dosing rules that come with it. As your complete GLP-1 resource — injections and pills alike — WeightLossInjections.com built this guide to help you understand exactly what to expect.
Key Takeaways
- The Wegovy pill (oral semaglutide 25 mg) was FDA-approved December 22, 2025 and launched in January 2026 — the first oral GLP-1 approved specifically for weight loss.
- It uses the same active ingredient as injectable Wegovy (semaglutide) but at a much higher oral dose, enabled by an absorption technology called SNAC.
- In the OASIS 4 trial, participants lost an average of 16.6% of body weight at 64 weeks.
- Dosing rules are strict: take 25 mg once daily in the morning, on an empty stomach, with no more than 4 oz of water, and wait 30 minutes before eating, drinking, or taking other oral medications.
- The Wegovy pill also carries an indication for reducing major adverse cardiovascular events (MACE) in adults with established cardiovascular disease.
- It is a different, more heavily-restricted dosing regimen than Foundayo, which requires no fasting at all.
What Is the Wegovy Pill?
The Wegovy pill is Novo Nordisk’s oral tablet formulation of semaglutide, the same GLP-1 receptor agonist found in injectable Wegovy and Ozempic. What makes the oral version work is a co-formulation with SNAC — sodium N-the WeightLossInjections.com Staffcaprylate — an absorption enhancer that helps the fragile semaglutide peptide survive the stomach long enough to be absorbed. Because that absorption process is inefficient, the oral dose needed to achieve meaningful blood levels is far higher than the injectable dose: 25 mg by mouth versus 2.4 mg by injection weekly.
The FDA approved the Wegovy pill for chronic weight management in adults with obesity or who are overweight with at least one weight-related comorbidity, and separately for reducing the risk of major cardiovascular events — heart attack, stroke, and cardiovascular death — in adults with established cardiovascular disease. Novo Nordisk’s December 2025 press release confirmed the approval, and the drug reached pharmacies in January 2026.
OASIS 4: The Pivotal Weight-Loss Trial
OASIS 4 was the Phase 3 trial that supported the Wegovy pill’s weight-loss indication. Over 64 weeks, participants taking the 25 mg oral semaglutide dose lost an average of approximately 16.6% of their body weight — a result that actually slightly exceeds the roughly 14.9% seen with injectable Wegovy in the STEP program, largely attributable to differences in trial design, population, and duration. OASIS 4 is part of a broader OASIS trial program (OASIS 1 through 4) that also generated supporting data for type 2 diabetes and other obesity-related outcomes. Full trial data and prescribing information are available in Novo Nordisk’s OASIS 4 publications and the Wegovy pill’s FDA prescribing information.
How to Take the Wegovy Pill
Unlike Foundayo, the Wegovy pill comes with a strict dosing routine because it’s a peptide-based drug that depends on the SNAC absorption enhancer working correctly:
- Take once daily, first thing in the morning
- Take on an empty stomach
- Use no more than 4 ounces of plain water to swallow the tablet
- Wait at least 30 minutes before eating, drinking anything else, or taking other oral medications
Missing any part of this routine — taking it with food, using too much water, or not waiting the full 30 minutes — can significantly reduce how much of the drug actually gets absorbed. This is one of the biggest practical differences between the Wegovy pill and Foundayo, which has no such requirements. If daily fasting rules feel burdensome, it’s worth discussing alternatives like Foundayo or injectable options with your provider.
Our Top 3 · July 2026
The best GLP-1 providers right now
Independently reviewed. Ranked by price, medication access, provider quality, and patient outcomes.
Renew GLP
Personalized GLP-1, GIP plans: Semaglutide & Tirzepatide.
Medvi
No membership or hidden fees. Everything you need is included.
Trimi
US-licensed clinicians and shipped to your door, from $99/mo.
Wegovy Pill vs. Injectable Wegovy vs. Foundayo
| Feature | Wegovy pill | Wegovy injection | Foundayo |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Orforglipron |
| Molecule type | Peptide | Peptide | Small-molecule |
| Dose | 25 mg oral, daily | 2.4 mg subcutaneous, weekly | Oral, daily |
| Fasting required? | Yes (strict) | N/A | No |
| Weight loss (trial) | ~16.6% (OASIS 4) | ~14.9% (STEP program) | 14.7-16.9% (ATTAIN-1) |
| MACE reduction indication | Yes | Yes | Not currently indicated |
| List price (approx.) | ~$1,349/month | Varies by plan | $149-349/month self-pay |
Why the Wegovy Pill Needs a Higher Dose Than Rybelsus
Both the Wegovy pill and Rybelsus contain semaglutide and use the same SNAC absorption technology, but they’re approved for different purposes at very different doses. Rybelsus tops out at 14 mg for type 2 diabetes management, a dose calibrated for blood sugar control rather than substantial weight loss. The Wegovy pill uses a considerably higher 25 mg dose specifically because meaningful weight loss requires more GLP-1 receptor activation than glycemic control alone. This is also why Rybelsus produces only modest weight loss (roughly 4-6 pounds as a secondary endpoint) while the Wegovy pill produces results comparable to injectable GLP-1 therapy. For more on that distinction, see our guide to Rybelsus for weight loss.
Cardiovascular Benefit: The MACE Indication
Beyond weight loss, the Wegovy pill carries an FDA indication for reducing major adverse cardiovascular events in adults with established cardiovascular disease — a distinction shared with injectable Wegovy but not currently held by Foundayo or Rybelsus. This makes the Wegovy pill a relevant option for patients managing both weight and cardiovascular risk, though the decision to prescribe for this indication rests with a cardiologist or primary care provider evaluating the full clinical picture.
Safety Considerations
The Wegovy pill shares the safety profile common to semaglutide products: nausea, vomiting, diarrhea, constipation, and decreased appetite, generally most intense during dose titration. Like all GLP-1 receptor agonists, it carries a boxed warning for the risk of thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Other class-wide precautions include pancreatitis, gallbladder disease, and acute kidney injury risk from dehydration (particularly relevant given the GI side effects). Always review the full FDA prescribing information with your healthcare provider before starting treatment.
Who Might Consider the Wegovy Pill
The Wegovy pill tends to be a good fit for people who want semaglutide’s well-documented weight-loss profile but prefer to avoid a weekly injection, and who feel confident they can consistently follow a morning fasting routine. It may also be particularly relevant for patients managing both obesity and established cardiovascular disease, given its dual weight-loss and MACE-reduction indication — something Foundayo does not currently carry. On the other hand, patients with unpredictable morning schedules, frequent travel across time zones, or difficulty sticking to fasting windows may find Foundayo’s no-restriction dosing easier to sustain long-term. Since both drugs are FDA-approved specifically for weight loss, the decision often comes down to lifestyle fit, insurance coverage, and how your body responds during an initial trial period — all best discussed with a healthcare provider familiar with your medical history.
It’s also worth noting that the Wegovy pill and injectable Wegovy are not interchangeable without medical guidance, even though they share an active ingredient. Switching from one form to the other, or from another GLP-1 like Ozempic or Mounjaro, involves dose recalibration that should only be managed by a prescriber.
FAQ
Is the Wegovy pill the same drug as the Wegovy injection?
Yes, both use semaglutide as the active ingredient, but the oral version requires a much higher dose (25 mg) than the injectable (2.4 mg weekly) because absorption through the digestive tract is less efficient.
How much weight can you lose with the Wegovy pill?
In the OASIS 4 trial, participants lost an average of about 16.6% of body weight over 64 weeks. Individual results vary based on dose, adherence, and other factors.
Do you have to fast to take the Wegovy pill?
Yes. It must be taken on an empty stomach in the morning with no more than 4 ounces of water, followed by a 30-minute wait before eating, drinking, or taking other oral medications.
Is the Wegovy pill better than Foundayo?
Neither is universally “better” — OASIS 4 data shows slightly higher average weight loss with the Wegovy pill (~16.6%) than the lower end of Foundayo’s ATTAIN-1 range, but Foundayo requires no fasting at all, which many patients find easier to sustain. The right choice depends on individual priorities and should be discussed with a healthcare provider.
When did the Wegovy pill become available?
The FDA approved it on December 22, 2025, and it became commercially available in January 2026.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Foundayo (orforglipron), Wegovy pill (oral semaglutide 25 mg), and Rybelsus (oral semaglutide 3/7/14 mg) are prescription medications with important safety information and contraindications. Discuss any medication decision with a qualified healthcare provider. Content published by WeightLossInjections.com, your complete resource for GLP-1 medications — injections and pills alike.
